Latest Updates
-
Yamuna Boat Capsize Near Vrindavan Leaves 10 Dead, 5 Missing: Boat Safety Checks Travellers Often Miss -
One Pot Tangy Lunch: The Ultimate Tomato Rice Recipe -
National Safe Motherhood Day 2026: Kasturba Gandhi’s Birth Anniversary Highlights India’s Maternal Health Gaps -
Jyotirao Phule Jayanti 2026: The Man Who Opened Classrooms India Tried To Keep Shut For Many -
World Parkinson’s Day 2026: Date, History, Significance, and Why It Matters -
Masala Chai Recipe: The Perfect Kadak Tea Formula -
Horoscope for Today Apr 11, 2026 - Small Choices, Steady Progress -
Inside Anant Ambani’s 31st Birthday Bash: Celebrities, Live Performances, And Large-Scale Seva Across India -
Paneer Masala Recipe: Unveiling the Rich Gravy Secret Method -
Fashion Hacks 101: From Hourglass To Broad, Saree Styling That Actually Flatters Every Body Type
Actos Reduces Conversion To Type 2 Diabetes
A new study has shown that people in prediabetic state were 81 pct less likely to convert into type 2 diabetes patients when treated with drug pioglitazone, brand name Actos®.
Lead researcher Dr. Ralph A. DeFronzo, professor and chief of diabetes at The University of Texas Health Science Center at San Antonio, said the study also showed that the patients randomized to take pioglitazone also recovered part of their insulin production and their bodies became more sensitive to insulin, therefore using it more efficiently to control plasma glucose or blood sugar,
“Prediabetes, I believe, is really diabetes," said Dr. DeFronzo.
The study involved 602 individuals with impaired glucose tolerance, a prediabetic state, along with 102 healthy controls.
Pioglitazone corrects two core defects in type 2 diabetes, insulin resistance and beta cell failure. Beta cells are the cells in the pancreas that secrete insulin.
“The drug is the best insulin sensitizer we have and it also preserves beta cell function. The clinical response in this study is next to astronomical, not 100 percent but obviously highly significant."
The findings revealed that 10 subjects with impaired glucose tolerance developed diabetes while taking pioglitazone as compared to 45 subjects with impaired glucose tolerance who developed diabetes after receiving a placebo.
It also showed that 42 percent of individuals in the pioglitazone arm of the study returned to normal glucose tolerance at the study"s end versus 28 percent of those in the placebo arm.
Currently, no drug is approved by the U.S. Food and Drug Administration for treatment of prediabetes to prevent progression to diabetes.
A drug to treat impaired glucose tolerance and prevent further decline is therefore of great importance.
The findings were presented on June 9 during the 68th Scientific Sessions of the American Diabetes Association in San Francisco.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications











